Edwards Lifesciences Corporation Common Stock

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -127.5 M280.4 M290.2 M573.7 M450.9 M43.8 M 1.36 B Mittelzufluss aus Investitionstätigkeit -576.7 M85.3 M-172.1 M-427.8 M-198.3 M-92.8 M -891 M Zahlungsströme aus der Finanzierungstätigkeit 28.6 M-258 M52.7 M-740.1 M-11.4 M-451.2 M -1.15 B Freier Cashflow -127.5 M280.4 M240.9 M516.2 M353.5 M-21.1 M 1.09 B

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.

EW

Financials

Edwards Lifesciences Corporation Common Stock

Nachrichten

OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?

Edwards Lifesciences: Top-Manager Donald Bobo Jr. verkauft Aktien im Wert von 2 Mio. US-Dollar

Edwards Lifesciences: Aktie klettert auf 52-Wochen-Hoch bei 87,89 USD

Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth

S&P 500 Top Stock Gainers Today, 5/22/26 - TipRanks.com

Edwards Lifesciences: CVP Lippis veräußert Aktien im Wert von 50.306 US-Dollar

Are Wall Street Analysts Bullish on Edwards Lifesciences Stock?

Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Edwards Lifesciences: CVP Wayne Markowitz verkauft Aktien im Wert von 47.279 $

Boston Scientific: Poised To Rebound With The Healthcare Sector, But When? (NYSE:BSX)

Edwards Lifesciences: TAVR-Chef verkauft Aktien im Wert von 170.160 US-Dollar

Edwards Lifesciences ernennt Doretta Mistras zur neuen Finanzchefin